Seán Olann Whelan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seán Olann Whelan has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Frank Moriarty
School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
4 shared publications- Frank Moriarty
School of Pharmacy and Biomolecular Sciences RCSI University of Medicine and Health Sciences Dublin Ireland
3 shared publications Ani Movsisyan
Consultant to Methods and Standards Team, World Health Organization, Geneva
2 shared publicationsCatherine King
2 shared publications- Corinna Sadlier
Department of Medicine, University College Cork, Cork, Ireland
2 shared publications Declan Devane
Evidence Synthesis Ireland and Cochrane Ireland, University of Galway, Galway
2 shared publications
Latest Publications
- 20 August 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (9) , 682
Interleukin-6 as a sepsis biomarker in neonatal and pediatric care: A retrospective real world cohort study
- 20 August 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (9) , 682
Interleukin-6 as a sepsis biomarker in neonatal and pediatric care: A retrospective real world cohort study
- Open Access
- 6 April 2026
- Published by Elsevier in SSRN Electronic Journal
Maternal Respiratory Syncytial Virus Vaccination for Infant Protection: Updated Systematic Review and Meta-Analysis of Efficacy, Effectiveness, and Safety
Background: Respiratory syncytial virus (RSV) is a major cause of severe illness in infants and young children.Method: We updated this systematic review to explore the efficacy, effectiveness and safety of authorised maternal RSV prefusion F (RSVpreF) vaccines for infant protection. We searched MEDLINE, Cochrane Library/Central, Embase and grey literature from 2000 to June 2025. We included randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs). Two independent authors performed screening, data extraction, and risk-of-bias assessment following standard methods. The PROSPERO registration number is CRD42023439128.Results: Meta-analyses of RCTs showed that maternal RSVpreF vaccines lowered medically attended RSV-related lower respiratory tract infections with vaccine efficacy of 68% (relative risk (RR) 0.32; 95% confidence interval (CI) 0.13 to 0.77, 2 trials; 7,656 participants; high certainty of evidence (CoE)), severe RSV-related lower respiratory tract infections with a vaccine efficacy of 84% (RR 0.16; 95% CI 0.07 to 0.36, 2 trials; 7,656 participants, high CoE) and RSV-related hospitalisations with a vaccine efficacy of 70% (RR 0.30; 95% CI 0.15 to 0.61, 1 trial; 7,148 participants, high CoE) in infants. There may be little to no difference in RSV-related mortality, all-cause mortality, vaccine-related serious adverse events, and intensive care admission. Requirements for invasive ventilation and duration of hospitalisation due to RSV disease were not reported by any trials. NRSIs suggested comparable effectiveness against hospitalisation, but certainty was very low (vaccine effectiveness of 72%; RR 0.28; 95% CI: 0.17 to 0.46, 3 NRSIs; 1,229 participants, very low CoE).Interpretation: Maternal RSVpreF vaccination reduced medically attended and severe RSV-LRTI and RSV-related hospitalisation in infants. No safety signals were identified. Further research is required to clarify the long-term effectiveness of vaccines.
- 6 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMaternal Respiratory Syncytial Virus Vaccination for Infant Protection: Updated Systematic Review and Meta-Analysis of Efficacy, Effectiveness, and Safety
Background: Respiratory syncytial virus (RSV) is a major cause of severe illness in infants and young children.Method: We updated this systematic review to explore the efficacy, effectiveness and safety of authorised maternal RSV prefusion F (RSVpreF) vaccines for infant protection. We searched MEDLINE, Cochrane Library/Central, Embase and grey literature from 2000 to June 2025. We included randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs). Two independent authors performed screening, data extraction, and risk-of-bias assessment following standard methods. The PROSPERO registration number is CRD42023439128.Results: Meta-analyses of RCTs showed that maternal RSVpreF vaccines lowered medically attended RSV-related lower respiratory tract infections with vaccine efficacy of 68% (relative risk (RR) 0.32; 95% confidence interval (CI) 0.13 to 0.77, 2 trials; 7,656 participants; high certainty of evidence (CoE)), severe RSV-related lower respiratory tract infections with a vaccine efficacy of 84% (RR 0.16; 95% CI 0.07 to 0.36, 2 trials; 7,656 participants, high CoE) and RSV-related hospitalisations with a vaccine efficacy of 70% (RR 0.30; 95% CI 0.15 to 0.61, 1 trial; 7,148 participants, high CoE) in infants. There may be little to no difference in RSV-related mortality, all-cause mortality, vaccine-related serious adverse events, and intensive care admission. Requirements for invasive ventilation and duration of hospitalisation due to RSV disease were not reported by any trials. NRSIs suggested comparable effectiveness against hospitalisation, but certainty was very low (vaccine effectiveness of 72%; RR 0.28; 95% CI: 0.17 to 0.46, 3 NRSIs; 1,229 participants, very low CoE).Interpretation: Maternal RSVpreF vaccination reduced medically attended and severe RSV-LRTI and RSV-related hospitalisation in infants. No safety signals were identified. Further research is required to clarify the long-term effectiveness of vaccines.
- Open Access
- 6 April 2026
- Published by Elsevier in SSRN Electronic Journal
Respiratory Syncytial Virus Vaccines in Older Adults: Results of An Updated Systematic Review and Meta-Analysis
Background: Respiratory syncytial virus (RSV) poses a major health risk to older adults.Methods: We updated a systematic review on the efficacy, effectiveness and safety of RSV vaccines in older adults. Literature searches of Medline, the Cochrane Library/CENTRAL, Embase, and grey literature were conducted for studies published from 2000 to June 2025. Two reviewers independently performed screening, data extraction, and risk-of-bias assessment. We included both randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs). PROSPERO registration is CRD42023439128.Results: We identified three RCTs and six NRSIs. RCT meta-analyses showed that RSV prefusion vaccines reduced RSV-associated lower respiratory tract illness in the first season, with vaccine efficacy of 77% (relative risk (RR) 0.23; 95% Confidence Interval (CI) 0.13–0.38, 3 trials; 96,172 participants, high certainty of evidence (CoE)), and reduced RSV-associated acute respiratory illness with vaccine efficacy of 67% (RR 0.33; 95% CI 0.26–0.42, 3 trials; 96,172 participants, high CoE), and may reduce hospitalisation (RR 0.33; 95% CI 0.07 to 1.66; 1 trial; 24,967 participants; low CoE). Based on the RCT results, there may be little to no difference in all-cause mortality and vaccine-related serious adverse events (SAEs) between the vaccine and placebo groups. The trials did not assess RSV-related mortality or intensive care outcomes. The NRSI meta-analysis suggested 76% effectiveness against laboratory-confirmed RSV illness (RR 0.24; 95% CI: 0.21 to 0.28; 3 NRSIs; 1,081,807 participants, low CoE) and 76% effectiveness against hospitalisation due to RSV disease (RR 0.24; 95% CI: 0.22 to 0.26; 5 NRSIs; 1,128,538 participants, low CoE).Interpretation: RSV prefusion vaccines were found to be efficacious, and there may be little to no difference in vaccine-related SAEs compared with placebo among older adults. Further research should determine the duration of protection offered by RSV prefusion vaccines and their effectiveness across different populations and settings.
- 6 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRespiratory Syncytial Virus Vaccines in Older Adults: Results of An Updated Systematic Review and Meta-Analysis
Background: Respiratory syncytial virus (RSV) poses a major health risk to older adults.Methods: We updated a systematic review on the efficacy, effectiveness and safety of RSV vaccines in older adults. Literature searches of Medline, the Cochrane Library/CENTRAL, Embase, and grey literature were conducted for studies published from 2000 to June 2025. Two reviewers independently performed screening, data extraction, and risk-of-bias assessment. We included both randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs). PROSPERO registration is CRD42023439128.Results: We identified three RCTs and six NRSIs. RCT meta-analyses showed that RSV prefusion vaccines reduced RSV-associated lower respiratory tract illness in the first season, with vaccine efficacy of 77% (relative risk (RR) 0.23; 95% Confidence Interval (CI) 0.13–0.38, 3 trials; 96,172 participants, high certainty of evidence (CoE)), and reduced RSV-associated acute respiratory illness with vaccine efficacy of 67% (RR 0.33; 95% CI 0.26–0.42, 3 trials; 96,172 participants, high CoE), and may reduce hospitalisation (RR 0.33; 95% CI 0.07 to 1.66; 1 trial; 24,967 participants; low CoE). Based on the RCT results, there may be little to no difference in all-cause mortality and vaccine-related serious adverse events (SAEs) between the vaccine and placebo groups. The trials did not assess RSV-related mortality or intensive care outcomes. The NRSI meta-analysis suggested 76% effectiveness against laboratory-confirmed RSV illness (RR 0.24; 95% CI: 0.21 to 0.28; 3 NRSIs; 1,081,807 participants, low CoE) and 76% effectiveness against hospitalisation due to RSV disease (RR 0.24; 95% CI: 0.22 to 0.26; 5 NRSIs; 1,128,538 participants, low CoE).Interpretation: RSV prefusion vaccines were found to be efficacious, and there may be little to no difference in vaccine-related SAEs compared with placebo among older adults. Further research should determine the duration of protection offered by RSV prefusion vaccines and their effectiveness across different populations and settings.
- 10 January 2026
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 318, 114936
The utility of interleukin-6 compared to conventional sepsis biomarkers in pregnancy – A real-world cohort study
- 10 January 2026
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 318, 114936
The utility of interleukin-6 compared to conventional sepsis biomarkers in pregnancy – A real-world cohort study
- Open Access
- 24 April 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (7) , 3063-3071
Pediatric blood cultures—turning up the volume: a before and after intervention study
The major determinant of blood culture (BC) diagnostic performance is blood volume, and pediatric sample volumes are frequently low. We aimed to assess BC volumes in our institution, design an intervention to increase volumes, and assess its impact. All pediatric BCs submitted over a 7-month period to the microbiology laboratory in a university hospital (including emergency department, pediatric ward, and neonatal unit) were included. A pre-intervention period assessed current practice. A multi-faceted intervention (education, guideline introduction, active feedback strategies) was collaboratively designed by all stakeholders. Impact was assessed in a post-intervention period. The main outcome measures included the percentage of samples adequately filled using three measures of sample adequacy (1) manufacturer-recommended minimum validated volume—> 0.5 ml, (2) manufacturer-recommended optimal minimum volume—> 1.0 ml, (3) newly introduced age-specific recommendations. Three hundred ninety-eight pre-intervention and 388 post-intervention samples were included. Initial volumes were low but increased significantly post-intervention (median 0.77 ml vs. 1.52 ml), with multivariable regression analysis estimating volumes increased 89% post-intervention. There were significant increases in all measures of volume adequacy, including an increase in age-appropriate filling (20.4–53.1%), with less improvement in those aged > 3 years. Overall, 68.4% of pathogens were from adequately filled cultures, while 76% of contaminants were from inadequately filled cultures. A pathogen was detected in a higher proportion of adequately filled than inadequately filled cultures (9.4% vs. 2.2%, p < 0.001). Conclusion: Blood volume impacts BC sensitivity, with lower volumes yielding fewer pathogens and more contaminants. Focused intervention can significantly improve volumes to improve diagnostic performance. What is Known:• Blood volume is the major determinant of blood culture positivity, and yet pediatric blood culture volumes are frequently low, resulting in missed pathogens and increased contamination. What is New:• Adequately filled (for age) blood cultures have a pathogen detection rate three times higher than inadequately filled blood cultures.• This interventional study shows that collaboratively designed multi-modal interventions including focus on accurate volume measurement can lead to significant increases in blood volumes and improve blood culture diagnostic performance.
- 24 April 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (7) , 3063-3071
Open AccessPediatric blood cultures—turning up the volume: a before and after intervention study
The major determinant of blood culture (BC) diagnostic performance is blood volume, and pediatric sample volumes are frequently low. We aimed to assess BC volumes in our institution, design an intervention to increase volumes, and assess its impact. All pediatric BCs submitted over a 7-month period to the microbiology laboratory in a university hospital (including emergency department, pediatric ward, and neonatal unit) were included. A pre-intervention period assessed current practice. A multi-faceted intervention (education, guideline introduction, active feedback strategies) was collaboratively designed by all stakeholders. Impact was assessed in a post-intervention period. The main outcome measures included the percentage of samples adequately filled using three measures of sample adequacy (1) manufacturer-recommended minimum validated volume—> 0.5 ml, (2) manufacturer-recommended optimal minimum volume—> 1.0 ml, (3) newly introduced age-specific recommendations. Three hundred ninety-eight pre-intervention and 388 post-intervention samples were included. Initial volumes were low but increased significantly post-intervention (median 0.77 ml vs. 1.52 ml), with multivariable regression analysis estimating volumes increased 89% post-intervention. There were significant increases in all measures of volume adequacy, including an increase in age-appropriate filling (20.4–53.1%), with less improvement in those aged > 3 years. Overall, 68.4% of pathogens were from adequately filled cultures, while 76% of contaminants were from inadequately filled cultures. A pathogen was detected in a higher proportion of adequately filled than inadequately filled cultures (9.4% vs. 2.2%, p < 0.001). Conclusion: Blood volume impacts BC sensitivity, with lower volumes yielding fewer pathogens and more contaminants. Focused intervention can significantly improve volumes to improve diagnostic performance. What is Known:• Blood volume is the major determinant of blood culture positivity, and yet pediatric blood culture volumes are frequently low, resulting in missed pathogens and increased contamination. What is New:• Adequately filled (for age) blood cultures have a pathogen detection rate three times higher than inadequately filled blood cultures.• This interventional study shows that collaboratively designed multi-modal interventions including focus on accurate volume measurement can lead to significant increases in blood volumes and improve blood culture diagnostic performance.
- 3 April 2024
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (4) , 1891-1900
Paediatric Escherichia coli urinary tract infection: susceptibility trends and clinical management—a retrospective analysis of a 10-year period
Background Escherichia coli is the predominant urinary pathogen in children. Irish and international studies have demonstrated increasing antimicrobial resistance (AMR) to antibiotics such as co-amoxiclav. Aims We aimed to (1) examine the AMR patterns of paediatric urinary E. coli isolates, from both hospital and community sources, over a 10-year period; (2) assess the effectiveness of Children’s Health Ireland (CHI) antimicrobial guidance given local susceptibility data; and (3) review the clinical management of an admitted patient sub-set over a 6-year period. Methods Pure growth of urinary E. coli from patients aged ≤ 14 from 2012 to 2021 were analysed for AMR. Differences in susceptibility rates were assessed. A retrospective chart review conducted on inpatients aged ≥ 2 months to ≤ 14 years, 2016–2021. Results E. coli accounted for 70.8% of likely significant positive pure growth cultures (9314 isolates). Susceptibility to co-amoxiclav significantly increased over time, from 66.7% to 80.4% (2016–2021, p < 0.001). Nitrofurantoin and cefalexin had significantly higher susceptibility rates than trimethoprim (< 70% annually). 85.1% of isolates were susceptible to the combination of co-amoxiclav and gentamicin, recommended for those > 2months and systemically unwell. The additional gain in empiric susceptibility provided by gentamicin above that provided by co-amoxiclav alone has fallen from 16.4% to 6.7% (2016–2021). The 222 clinical cases reviewed showed improved antimicrobial guideline compliance over time. Conclusions This study provides important regional AMR data. Co-amoxiclav susceptibility increased significantly over time, contrasting with previous studies. This was temporally associated with stewardship measures reducing co-amoxiclav prescribing. Decreasing utility of gentamicin supports recent CHI guideline updates reducing gentamicin use.
- 3 April 2024
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (4) , 1891-1900
Paediatric Escherichia coli urinary tract infection: susceptibility trends and clinical management—a retrospective analysis of a 10-year period
Background Escherichia coli is the predominant urinary pathogen in children. Irish and international studies have demonstrated increasing antimicrobial resistance (AMR) to antibiotics such as co-amoxiclav. Aims We aimed to (1) examine the AMR patterns of paediatric urinary E. coli isolates, from both hospital and community sources, over a 10-year period; (2) assess the effectiveness of Children’s Health Ireland (CHI) antimicrobial guidance given local susceptibility data; and (3) review the clinical management of an admitted patient sub-set over a 6-year period. Methods Pure growth of urinary E. coli from patients aged ≤ 14 from 2012 to 2021 were analysed for AMR. Differences in susceptibility rates were assessed. A retrospective chart review conducted on inpatients aged ≥ 2 months to ≤ 14 years, 2016–2021. Results E. coli accounted for 70.8% of likely significant positive pure growth cultures (9314 isolates). Susceptibility to co-amoxiclav significantly increased over time, from 66.7% to 80.4% (2016–2021, p < 0.001). Nitrofurantoin and cefalexin had significantly higher susceptibility rates than trimethoprim (< 70% annually). 85.1% of isolates were susceptible to the combination of co-amoxiclav and gentamicin, recommended for those > 2months and systemically unwell. The additional gain in empiric susceptibility provided by gentamicin above that provided by co-amoxiclav alone has fallen from 16.4% to 6.7% (2016–2021). The 222 clinical cases reviewed showed improved antimicrobial guideline compliance over time. Conclusions This study provides important regional AMR data. Co-amoxiclav susceptibility increased significantly over time, contrasting with previous studies. This was temporally associated with stewardship measures reducing co-amoxiclav prescribing. Decreasing utility of gentamicin supports recent CHI guideline updates reducing gentamicin use.
- Open Access
- 11 October 2023
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 5, 69
Effect of COVID-19 vaccines for the treatment of people with post-COVID-19 condition: a rapid review
Background: Vaccination for coronavirus disease 2019 (COVID-19) has demonstrated reduced risk of hospitalisation and death against more recent variants of COVID-19. Some studies suggested improvements in patients with post-COVID-19 condition (PCC) following vaccination. We systematically explored available evidence on the effect of COVID-19 vaccines on the treatment of people with PCC. Methods: We conducted a rapid review of the literature following systematic approaches. We searched Medline (OVID), EMBASE (Elsevier), ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) for randomised trials, non-randomised trials, controlled before-after studies, and interrupted time-series studies of the effect of COVID-19 vaccines for treating people with PCC. Two independent review authors screened citations. Two review authors extracted data independently. We had planned to assess the risk of bias and use the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation) to assess the certainty of evidence if there were completed studies. Results: We identified two ongoing randomised controlled trials. Both trials examine the effectiveness of therapeutic vaccines on PCC. The anticipated completion date of the CIMAvax-EGFA trial is January 2023, and the completion date of the COVID-19 mRNA vaccine trial is not stated. Conclusions: There is currently an absence of high‐quality evidence evaluating the effectiveness of COVID-19 vaccines for treating people with post-COVID-19 condition. The absence of published studies and only two ongoing trials highlight the need for additional studies on the effectiveness of vaccines for PCC. We recommend that researchers consider PCC as per the definition provided by the World Health Organization and use the available core outcome set for PCC in deciding which outcomes to measure and report in the trials. PROPSERO registration: CRD42022330821 (20/06/2022)
- 11 October 2023
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 5, 69
Open AccessEffect of COVID-19 vaccines for the treatment of people with post-COVID-19 condition: a rapid review
Background: Vaccination for coronavirus disease 2019 (COVID-19) has demonstrated reduced risk of hospitalisation and death against more recent variants of COVID-19. Some studies suggested improvements in patients with post-COVID-19 condition (PCC) following vaccination. We systematically explored available evidence on the effect of COVID-19 vaccines on the treatment of people with PCC. Methods: We conducted a rapid review of the literature following systematic approaches. We searched Medline (OVID), EMBASE (Elsevier), ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) for randomised trials, non-randomised trials, controlled before-after studies, and interrupted time-series studies of the effect of COVID-19 vaccines for treating people with PCC. Two independent review authors screened citations. Two review authors extracted data independently. We had planned to assess the risk of bias and use the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation) to assess the certainty of evidence if there were completed studies. Results: We identified two ongoing randomised controlled trials. Both trials examine the effectiveness of therapeutic vaccines on PCC. The anticipated completion date of the CIMAvax-EGFA trial is January 2023, and the completion date of the COVID-19 mRNA vaccine trial is not stated. Conclusions: There is currently an absence of high‐quality evidence evaluating the effectiveness of COVID-19 vaccines for treating people with post-COVID-19 condition. The absence of published studies and only two ongoing trials highlight the need for additional studies on the effectiveness of vaccines for PCC. We recommend that researchers consider PCC as per the definition provided by the World Health Organization and use the available core outcome set for PCC in deciding which outcomes to measure and report in the trials. PROPSERO registration: CRD42022330821 (20/06/2022)
- Open Access
- 25 October 2022
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 5, 69
Effect of COVID-19 vaccines for the treatment of people with post-COVID-19 condition: a rapid review
Background: Vaccination for coronavirus disease 2019 (COVID-19) has demonstrated reduced risk of hospitalisation and death against more recent variants of COVID-19. Some studies suggested improvements in patients with post-COVID-19 condition (PCC) following vaccination. We systematically explored available evidence on the effect of COVID-19 vaccines for the treatment of people with PCC. Methods: We conducted a rapid review of the literature following systematic approaches. We searched Medline (OVID), EMBASE (Elsevier), ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) for randomised trials, non-randomised trials, controlled before-after studies, and interrupted time-series studies of the effect of COVID-19 vaccines for treating people with PCC. Two independent review authors screened citations. Two review authors extracted data independently. We had planned to assess the risk of bias and use the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation) to assess the certainty of evidence if there were completed studies. Results: We identified two ongoing randomised controlled trials. Both trials examine the effectiveness of therapeutic vaccines on PCC. The anticipated completion date of the CIMAvax-EGFA trial is January 2023, and the completion date of the COVID-19 mRNA vaccine trial is not stated. Conclusions: There is currently an absence of high‐quality evidence evaluating the effectiveness of COVID-19 vaccines for treating people with post-COVID-19 condition. The absence of published studies and only two ongoing trials highlight the need for additional studies on the effectiveness of vaccines for PCC. We recommend that researchers consider PCC as per the definition provided by the World Health Organization and use the available core outcome set for PCC in deciding which outcomes to measure and report in the trials. PROPSERO registration: CRD42022330821 (20/06/2022)
- 25 October 2022
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 5, 69
Open AccessEffect of COVID-19 vaccines for the treatment of people with post-COVID-19 condition: a rapid review
Background: Vaccination for coronavirus disease 2019 (COVID-19) has demonstrated reduced risk of hospitalisation and death against more recent variants of COVID-19. Some studies suggested improvements in patients with post-COVID-19 condition (PCC) following vaccination. We systematically explored available evidence on the effect of COVID-19 vaccines for the treatment of people with PCC. Methods: We conducted a rapid review of the literature following systematic approaches. We searched Medline (OVID), EMBASE (Elsevier), ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) for randomised trials, non-randomised trials, controlled before-after studies, and interrupted time-series studies of the effect of COVID-19 vaccines for treating people with PCC. Two independent review authors screened citations. Two review authors extracted data independently. We had planned to assess the risk of bias and use the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation) to assess the certainty of evidence if there were completed studies. Results: We identified two ongoing randomised controlled trials. Both trials examine the effectiveness of therapeutic vaccines on PCC. The anticipated completion date of the CIMAvax-EGFA trial is January 2023, and the completion date of the COVID-19 mRNA vaccine trial is not stated. Conclusions: There is currently an absence of high‐quality evidence evaluating the effectiveness of COVID-19 vaccines for treating people with post-COVID-19 condition. The absence of published studies and only two ongoing trials highlight the need for additional studies on the effectiveness of vaccines for PCC. We recommend that researchers consider PCC as per the definition provided by the World Health Organization and use the available core outcome set for PCC in deciding which outcomes to measure and report in the trials. PROPSERO registration: CRD42022330821 (20/06/2022)
- Open Access
- 2 July 2022
- Published by Elsevier in EBioMedicine
- Vol. 81, 104110
Systematic review of host genomic biomarkers of invasive bacterial disease: Distinguishing bacterial from non-bacterial causes of acute febrile illness
- 2 July 2022
- Published by Elsevier in EBioMedicine
- Vol. 81, 104110
Open AccessSystematic review of host genomic biomarkers of invasive bacterial disease: Distinguishing bacterial from non-bacterial causes of acute febrile illness
- 27 March 2021
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 180 (9) , 2839-2847
Vaccine hesitancy and reported non-vaccination in an Irish pediatric outpatient population
Vaccine hesitancy is defined as a delay in acceptance, or refusal, of vaccines, despite availability. It is a complex and context specific phenomenon and identified as a global health priority. The “Parent Attitudes about Childhood Vaccines” (PACV) questionnaire is a validated tool for identifying vaccine hesitancy. Our aim was to use the PACV to assess vaccine hesitancy and its relationship with reported non-vaccination in an Irish population, for the first time. Our participants were parents or caregivers of children attending general pediatric clinics in a tertiary pediatric hospital in Dublin, Ireland, between September and December 2018. In total, 436 participants completed the questionnaire. 5.5% of our population reported non-vaccination. Human papilloma virus and measles, mumps, rubella vaccines were the most commonly cited vaccines of concern (11.5% and 6.7%, respectively), and autism spectrum disorder was the most commonly side effect of concern (4.3%). Mean PACV score was 26.9 (SD 19.1), with a significant difference between non-vaccinators and vaccinators (53.2 vs 25.3, pConclusion: PACV identified reported non-vaccination with high accuracy in our population. It may be useful to screen vaccine-hesitant parents who could benefit from interventions to improve uptake. What is Known: • Vaccine hesitancy is a leading threat to global health, with falls in vaccine uptake associated with disease outbreaks worldwide. • The Parent Attitudes about Childhood Vaccines (PACV) questionnaire is a validated measure of vaccine hesitancy and correlates with non-vaccination in many populations. What is New: • This large study in a pediatric outpatient clinic setting represents the first use of the PACV in a Western European population to assess vaccination hesitancy. • The PACV may be an effective way of screening a pediatric clinic population to identify vaccine-hesitant parents or caregivers for targeted vaccine promotion.
- 27 March 2021
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 180 (9) , 2839-2847
Vaccine hesitancy and reported non-vaccination in an Irish pediatric outpatient population
Vaccine hesitancy is defined as a delay in acceptance, or refusal, of vaccines, despite availability. It is a complex and context specific phenomenon and identified as a global health priority. The “Parent Attitudes about Childhood Vaccines” (PACV) questionnaire is a validated tool for identifying vaccine hesitancy. Our aim was to use the PACV to assess vaccine hesitancy and its relationship with reported non-vaccination in an Irish population, for the first time. Our participants were parents or caregivers of children attending general pediatric clinics in a tertiary pediatric hospital in Dublin, Ireland, between September and December 2018. In total, 436 participants completed the questionnaire. 5.5% of our population reported non-vaccination. Human papilloma virus and measles, mumps, rubella vaccines were the most commonly cited vaccines of concern (11.5% and 6.7%, respectively), and autism spectrum disorder was the most commonly side effect of concern (4.3%). Mean PACV score was 26.9 (SD 19.1), with a significant difference between non-vaccinators and vaccinators (53.2 vs 25.3, pConclusion: PACV identified reported non-vaccination with high accuracy in our population. It may be useful to screen vaccine-hesitant parents who could benefit from interventions to improve uptake. What is Known: • Vaccine hesitancy is a leading threat to global health, with falls in vaccine uptake associated with disease outbreaks worldwide. • The Parent Attitudes about Childhood Vaccines (PACV) questionnaire is a validated measure of vaccine hesitancy and correlates with non-vaccination in many populations. What is New: • This large study in a pediatric outpatient clinic setting represents the first use of the PACV in a Western European population to assess vaccination hesitancy. • The PACV may be an effective way of screening a pediatric clinic population to identify vaccine-hesitant parents or caregivers for targeted vaccine promotion.